Nuclear medicine communications
-
Comparative Study Clinical Trial
Usefulness of 99mTc ethyl cysteinate dimer brain SPECT to detect abnormal regional cerebral blood flow in patients with acute carbon monoxide poisoning.
99mTc ethyl cysteinate dimer (99mTc-ECD) brain single photon emission computed tomography (SPECT) was used to detect abnormal regional cerebral blood flow (rCBF) in patients with acute carbon monoxide (CO) poisoning. Ten patients with acute CO poisoning and no past histories of psychoneurological disorders were enrolled in this study. ⋯ Only three of the 10 patients had normal 99mTc-ECD brain SPECT findings. This study suggests that, in comparison with brain CT scan, 99mTc-ECD brain SPECT is a better tool for the early detection of hypoperfusion brain lesions in acute CO poisoning in patients with normal brain CT findings.
-
Comparative Study Clinical Trial
Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
Dual time-point imaging has been proposed as a means of improving the accuracy of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) for the diagnosis of malignant pulmonary nodules. The purpose of this study was to evaluate a dual time-point protocol that has a narrow time window between its initial and its delayed imaging sessions. All patients examined during a 16-month time period, either for the diagnosis of a radiographically indeterminate thoracic lesion or for the staging of non-small-cell carcinoma, were included in the study provided that they completed the dual-point protocol and had either biopsy evidence of malignancy, biopsy evidence of a benign condition involving the thoracic lesion of concern, or clinical and radiographic follow-up consistent with the absence of malignancy. ⋯ The best performance was achieved when the BSA corrected dSUV was at least 2.4, or when the fSUV showed at least a 5% increase from initial to delayed imaging. With the optimal combined dSUV/fSUV strategy, the area under the ROC curve was 0.99, as opposed to 0.96 for dSUV alone, or 0.93 for iSUV alone. The ability of 18F-FDG PET to discriminate between benign and malignant conditions of the central thorax can be improved by correcting the SUV for BSA and by increasing the 'incubation time' between 18F-FDG injection and imaging, or by performing narrow time-window dual-point imaging.